Evidence map›Paper›PMID 41757140›Full record

ReviewEuroasian journal of hepato-gastroenterology

The Sustainable Goal of Eliminating Hepatitis B, Functional Cure, and the Prospect of NASVAC: A Review.

Mamun Al Mahtab, Julio Ca Rubido, Gerardo E Guillen, Eduardo Penton, Osamu Yoshida, Yoichi Hiasa, Sakirul Khan, Md Abdur Rahim, Noor-E-Alam Mohammad, Ahmed L Moben and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Euroasian journal of hepato-gastroenterology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Mamun Al MahtabDepartment of Hepatology, Bangladesh Medical University, Dhaka, Bangladesh.ORCID https://orcid.org/0000-0003-3728-3879
Julio Ca RubidoDepartment of Vaccine Division, Biomedical Research Department, Center for Genetic Engineering and Biotechnology, Habana, Cuba.
Gerardo E GuillenDepartment of Biomedical Research, Center for Genetic Engineering and Biotechnology, Havana, Cuba.
Eduardo PentonDepartment of Vaccines, Center for Genetic Engineering and Biotechnology, Havana, Cuba.
Osamu YoshidaDepartment of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Shikoku, Japan.
Yoichi HiasaDepartment of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Shikoku, Japan.
Sakirul KhanDepartment of Microbiology, Oita University, Oita, Japan.
Md Abdur RahimDepartment of Hepatology, International Medical College, Gazipur, Bangladesh.ORCID https://orcid.org/0009-0006-1431-1143
Noor-E-Alam MohammadDepartment of Hepatology, Bangladesh Medical University, Dhaka, Bangladesh.ORCID https://orcid.org/0009-0004-0629-9637
Ahmed L MobenKurmitola General Hospital, Dhaka, Bangladesh.ORCID https://orcid.org/0000-0002-4862-7692
Rokshana BegumDepartment of Hepatology, Shaheed Suhrawardy Medical College, Dhaka, Bangladesh.ORCID https://orcid.org/0009-0003-3982-0970
Musarrat MahtabDepartment of Biochemistry and Biotechnology, North South University, Dhaka, Bangladesh.ORCID https://orcid.org/0009-0001-7344-4812
Sheikh Mf AkbarDepartment of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Shikoku, Japan.ORCID https://orcid.org/0000-0003-4537-3313

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis B is a global pandemic, being one of the rare infectious causes of the rising number of deaths globally, whereas these numbers are on the decline with all other major infections like malaria, tuberculosis, and HIV/AIDS, to name a few. We have useful antivirals against the hepatitis B virus (HBV) that can contain the disease, but we are still far away from the Holy Grail that will cure the disease once and forever. Having said so, this also has to be kept in mind that both the World Health Organization and the Sustainable Development Goal call for the effective elimination of this menace by 2030, which is a few years from now. The race is therefore on for developing the right cure for hepatitis B, and a therapeutic vaccine is one such candidate in the growing list of potential future cures for the virus. Here we discuss NASVAC, an immune-therapy for chronic hepatitis B, which is established as safe and efficacious against the virus and may well be the option that we are so eagerly looking forward to for achieving functional cure of hepatitis B to benefit the missing millions. How to cite this article: Mahtab MA, Rubido JCA, Guillen GE,

Indexed as

Functional cureHBsAg seroconversionHepatitis B virusImmune-therapyNASVAC

Identifiers

PMID41757140
PMCPMC12932396

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.